Ryan M P
Magnesium. 1984;3(4-6):274-88.
One of the most common and most serious side-effects of diuretic therapy is an increased urinary loss of potassium. Another, although less well publicized, side-effect of diuretic therapy is excessive loss of urinary magnesium. Loop-blocking diuretics, especially, cause major losses of urinary magnesium, and this is consistent with micropuncture studies in laboratory animals which indicate that the loop of Henle is a major site of magnesium reabsorption. Potassium-sparing diuretics such as amiloride can be administered concomitantly with more potent diuretics to counteract diuretic-induced potassium depletion. Amiloride may also exert magnesium-sparing actions. Our experimental investigations and clinical studies with congestive heart failure patients, providing evidence for both potassium- and magnesium-sparing actions of amiloride, will be discussed. In saline-loaded rats, the magnesium-sparing effect of amiloride was demonstrated when amiloride was administered either alone or in combination with furosemide. Renal clearance studies in rats indicated that the magnesium-sparing effect of amiloride was a direct renal action and not secondary to possible extra-renal actions. A dose-response relationship has been established for the actions of amiloride in reducing fractional excretion of magnesium and potassium during furosemide diuresis in rats. Congestive heart failure patients being treated with furosemide were found to be both potassium and magnesium deficient as indicated by reduced lymphocyte potassium and magnesium. In these patients, amiloride reduced urinary magnesium and potassium, increased plasma magnesium and potassium and also increased lymphocyte magnesium and potassium. The magnesium-sparing actions of amiloride may have important therapeutic implications in that many experimental and clinical studies from our laboratory and from other investigators have shown that magnesium plays an important role in the maintenance and restoration of cellular potassium.
利尿治疗最常见且最严重的副作用之一是钾的尿排泄增加。利尿治疗的另一个副作用,尽管宣传较少,是尿镁过度流失。尤其是袢利尿剂会导致大量尿镁流失,这与实验动物的微穿刺研究结果一致,该研究表明髓袢是镁重吸收的主要部位。保钾利尿剂如阿米洛利可与更强效的利尿剂联合使用,以抵消利尿剂引起的钾缺乏。阿米洛利也可能具有保镁作用。我们将讨论针对充血性心力衰竭患者进行的实验研究和临床研究,这些研究为阿米洛利的保钾和保镁作用提供了证据。在盐水负荷的大鼠中,单独给予阿米洛利或与呋塞米联合给予时,均显示出阿米洛利的保镁作用。大鼠的肾清除率研究表明,阿米洛利的保镁作用是直接的肾脏作用,而非继发于可能的肾外作用。在大鼠呋塞米利尿期间,已建立了阿米洛利减少镁和钾分数排泄作用的剂量反应关系。在用呋塞米治疗的充血性心力衰竭患者中,淋巴细胞钾和镁降低表明患者存在钾和镁缺乏。在这些患者中,阿米洛利减少了尿镁和尿钾,增加了血浆镁和钾,还增加了淋巴细胞镁和钾。阿米洛利的保镁作用可能具有重要的治疗意义,因为我们实验室和其他研究者的许多实验和临床研究表明,镁在维持和恢复细胞钾方面起着重要作用。